EBC-46
Compassionate use and expanded access programmes could allow cancer patients to receive tigilanol tiglate before formal Phase III approval — here is how the regulatory framework works.
EBC-46
Two plants share the name Blushwood, but only one contains EBC-46. A decade of media misidentification has wrongly attributed tigilanol tiglate to Hylandia dockrillii — here is the full story.
EBC-46
Verified buyers report striking results with blushwood berry extract — from inflammation and energy to skin changes and outcomes that surprised their doctors. Science should be paying attention.
EBC-46
Fontainea picrosperma grows only in north Queensland's Wet Tropics and produces a pharmacologically extraordinary compound. The full extent of what it can do remains one of botany's most compelling open questions.
EBC-46
Phase I human trials of tigilanol tiglate are evaluating safety in solid tumours. Early data suggests the tolerability profile mirrors what was observed in veterinary studies.
EBC-46
EBC-46 works by mimicking diacylglycerol to activate PKC-delta, triggering a cascade of vascular disruption and immune recruitment that destroys tumours from within.
EBC-46
Stelfonta became the first tigilanol tiglate product approved by the FDA. Understanding its regulatory journey maps the path EBC-46 must follow for human approval.
EBC-46
Intratumoral EBC-46 is designed to stay local — but how much reaches systemic circulation, and what does the body do with it? A detailed look at tigilanol tiglate pharmacokinetics.
EBC-46
EBC-46 has received Orphan Drug Designation from the FDA for specific rare cancers. Here's what that regulatory milestone actually means — and why it matters for patients.
EBC-46
When a local injection shrinks tumours far from the injection site, something remarkable is happening. Here's what research reveals about EBC-46 and systemic anti-tumour immunity.
Stelfonta
How EBC-46 became Stelfonta® — the first FDA and EMA approved intratumoral cancer treatment — through rigorous canine clinical trials, and what this milestone means for the ongoing Phase I/II human cancer trials.
Clinical Trials
A detailed review of EBC-46 (tigilanol tiglate) human clinical trial data through 2025–2026, including Phase I/II results for soft tissue sarcoma, melanoma, and other solid tumours, response rates, and the path to FDA approval.